Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Background:
Pancreatic cancer is one of the most lethal types of cancer. ASCP is a highly aggressive type
of pancreatic cancer. It is very rare. Researchers want to see if a drug called Minnelide can
be used to treat ASCP.
Objective:
To see if Minnelide is an effective treatment for ASCP.
Eligibility:
Adults ages 18 and older with ASCP whose cancer did not respond to previous treatments.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine samples
Evaluation of ability to do daily activities
Electrocardiogram to test heart function
Body and/or brain scans. For these, participants will lie in a machine that takes pictures of
the body. They may have a contrast agent injected into a vein.
Tumor sample. If one is not available, participants will have a tumor biopsy. The biopsy will
be taken with a small needle put through the skin into the tumor.
Treatment will be given in 28-day cycles, for up to 12 cycles. There is a 7-day resting
period between cycles. Participants will take Minnelide by mouth every day for 21 days of
each cycle. They will keep a medicine diary.
Participants will have at least 1 study visit every cycle. They will review their medicine
diary. They will repeat some screening tests.
Participants may have optional tumor biopsies. Some participants may need to take birth
control during the study and for up to 6 months after treatment.
Participants will have an end-of-treatment visit 4 weeks after they stop taking the study
drug. They will repeat some screening tests.